CS Diagnostics Corp (CSDX) is a Wyoming-incorporated medical technology company focused on developing, licensing, and commercializing diagnostic and therapeutic products. The company collaborates with universities, research institutions, and healthcare professionals to bring products to market, and provides international firms in the medical sector with regulatory approval services and market access in Europe and the MENA regions. As of the nine months ended September 30, 2025, the company remained in a transitional development-to-operational phase, with no revenue reported in the available financial excerpts. The balance sheet reflects an accumulated deficit and a stockholders' deficit position as of September 30, 2025. CSDX does not intend to pay cash dividends in the foreseeable future. The company is incorporated in Wyoming and is subject to FDA and equivalent international regulatory oversight for any pharmaceutical or diagnostic products it seeks to commercialize.

Revenue model

No revenue is reported in the available filing excerpts for the periods ended September 30, 2025. The company's stated intent is to generate revenue through product licensing, commercialization of diagnostic and therapeutic products, and regulatory consulting services for international medical firms seeking market access in Europe and the MENA regions.

Products and services

Diagnostic and therapeutic medical products developed in collaboration with universities and research institutions. Regulatory approval consulting services and market-access services for international medical sector firms targeting European and MENA markets.

Customers and end markets

International firms in the medical sector seeking regulatory approval and market access in Europe and the MENA regions. Healthcare professionals and research institutions are collaboration partners. End markets include pharmaceutical and medical diagnostics.

Value-chain role

Early-stage developer and licensor of diagnostic and therapeutic products. Acts as a regulatory and market-access intermediary for international medical firms. Relies on third-party universities and research institutions for product development collaboration.

Geographic exposure

Wyoming-based. Targets international market access in Europe and the MENA regions for its regulatory consulting services.

Source: SEC 10-Q, filed 2025-11-13

Industry: Specialty Cleaning, Polishing and Sanitation Preparations